Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024

About this update from Ligand Pharmaceuticals Incorporated

[{"type":"text","content":" JUPITER, Fla.--(BUSINESS WIRE)--\nLigand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. The company will hold a conference call that same day beginning at 8:30 a.m. ET to discuss the results and provide a general business update.\n\nConference Call and Webcast Information\n\n\n\nDate:\n\n\n\n\n\nThursday, November 7, 2024\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n\n\nTime:\n\n\n\n\n\n8:30 a.m. ET (5:30 a.m. PT)\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n\n\nConference Call:\n\n\n\n\n\n(888) 596-4144 (U.S. & Canada)\n\n\n\n\n\n \n\n\n\n\n\n(646) 968-2525 (International)\n\n\n\n\n\n \n\n\n\n\n\nConference ID is 8755336\n\n\n\n\n\n \n\n\n\n\n\n \n\n\n\n\n\nWebcast:\n\n\n\n\n\nLive and replay webcasts of the call are available here.\n\n\n\n\nAbout Ligand Pharmaceuticals\n\nLigand is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines. Ligand does this by providing financing, licensing our technologies or both. Its business model seeks to generate value for stockholders by creating a diversified portfolio of biopharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Ligand’s goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner. Its business model focuses on funding programs in mid- to late-stage drug development in return for economic rights, purchasing royalty rights in development stage or commercial biopharmaceutical products and licensing its technology to help partners discover and develop medicines. Ligand partners with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) in order to generate its revenue. Ligand’s Captisol® platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading biopharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. For more information, please visit ww...

More updates from Ligand Pharmaceuticals Incorporated